Insights
Insights From Our Experts
Articles
A Review of Indirect Treatment Comparisons (ITCs) in Regulatory Approval, Reimbursement and Pricing Recommendations for Oncology Drugs
Posted by
Krista Tantakoun , Christopher Olsen , Fatemeh Mirzayeh Fashami , Imtiaz Samjoo , Chris Cameron, PhD on November 19, 202411/19/24
The use of indirect treatment comparisons (ITCs) has increased significantly in recent years, particularly in the assessment of oncology and rare diseases where direct head-to-head trials may be impractical or unavailable, with numerous oncology and orphan…
Insights from SAHARA+ Conference: Harnessing Real-World Data and AI to Transform Healthcare
EVERSANA’s executive director and Middle East head, Prashant Pandarathil, recently presented at Saudi Arabia’s Healthcare Advancement for Resourceful Funding, Regulatory Excellence and Innovation (SAHARA+) Conference on the topic “Harnessing the Power of Real-World Data (RWD) and…
Finding the Human Element Amid the Algorithms
Posted on November 12, 202411/12/24
The programmatic buying and selling of health media is, ultimately, steered by the humans that enable it. So why does the notion that it’s a machine-driven process still linger? Spend more than a few minutes of…
Adherence Redefined: Evolving Approaches to Adherence in Oncology Clinical Pathways
Discover how leading cancer institutions are redefining adherence to clinical pathways. Our latest white paper, “Adherence Redefined: Evolving Approaches to Adherence in Oncology Clinical Pathways,” authored by EVERSANA MANAGEMENT CONSULTING, delves into the shifting landscape of oncology…
Comparing First-Line Treatments for mCRPC: Insights From a Comprehensive NMA
Several first-line (1L) pharmacological treatments are available for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), an incurable condition with poor prognosis and quality of life. Benefits to patient survival in clinical trials have…
New Insights into Brain Volume Loss in MS
We are excited to announce that members of the EVERSANA team have contributed to a significant publication in BMC Neurology. The study, titled “Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying…
3 Questions You Need to Answer Before Partnering With Integrated Delivery Networks
Posted by
Christopher Nuesch on October 15, 202410/15/24
Are you a pharmaceutical manufacturer looking to navigate the complex world of Integrated Delivery Networks (IDNs)? These powerful entities, which manage multiple healthcare facilities, are key players in delivering high-quality, cost-effective, and patient-centered care. But how…
OpenAI’s new o1 Series models’ focus on “reasoning” and what it could mean to lifesciences brands and marketers
By Abid Rahman, EVERSANA Technology continues to evolve faster than ever. That’s the case with the recent news that OpenAI has introduced a new series of artificial intelligence models they are calling their o1 series, which…
AI, Digital Therapeutics Transformation & Cross-Industry Collaboration – What’s On Tap at Frontiers Health
Frontiers Health global conference is just a few weeks away, and as founder and chairman of the event, it’s a special few days. Every year, Frontiers Health explores the most relevant health topics, leading the way…
Unlocking the Power of Tender Data to Drive Post-LOE Pricing Strategy
In the world of pharmaceuticals, pricing strategy becomes especially critical after the loss of exclusivity (LOE) for blockbuster drugs. Once patent protection ends, competition from generics or biosimilars floods the market, leading to significant price erosion.…